INFORMATION
Vedolizumab is a recombinant protein that has the potential to induce humoral immune responses and lead to anti-drug antibody formation; a major cause of loss of response.
These Anti-drug antibodies can bind and neutralise the drug accelerating its clearance and reducing its efficacy. Monitoring the efficacy of Vedolizumab may help clinicians schedule a successful individualised treatment strategy for their patients.
Free Anti-Vedolizumab Antibody ELISA
Free anti-drug antibody ELISAs (“drug sensitive assays”) enable the detection of anti-drug antibodies that are not bound to other proteins or therapeutic drugs.
IDKmonitor® Vedolizumab Free Anti-drug Antibody ELISA is a quantitative assay that detects human antibodies against Vedolizumab in EDTA plasma and serum samples by capturing the anti-Vedolizumab antibodies on the microplate.
FEATURES
-
Detects free anti-Vedolizumab Antibodies in Serum and Plasma
-
Microplate coated with highly specific Vedolizumab fragments
-
1 calibrator, 2 controls
-
Capacity for 45 samples in duplicate
-
Assay time 130 minutes
-
Automatable on ELISA automates (e.g. Dynex D2)
BENEFITS
-
Supports the investigation of primary non response and loss of response to Vedolizumab
-
Drug sensitive assay only detects free anti-Vedolizumab antibodies (those not bound to Vedolizumab)
-
May help predict long term outcome of disease in patients with sub-therapeutic Vedolizumab levels
-
UK publications and evidence base
-
Available via reference laboratories in UK
-
Applicable to Gastroenterology
